TrialInternational journal of clinical oncology2022

Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study.

Shunichi Sugawara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.